{
    "medicine_id": "e0c4cd4d135f684b761d0a751859021638903721",
    "platform_id": "DB00746",
    "metadata": {
        "name": "Deferoxamine 95 mg 1mL Injection powder lyophilized for solution",
        "composition": "95 mg 1mL Deferoxamine",
        "clinical_particulars": {
            "therapeutic_indications": "Used to treat acute iron or aluminum toxicity an excess of aluminum in the body in certain patients Also used in certain patients with anemia who must receive many blood transfusions",
            "contraindications": {
                "disease": "Intravenous LD sub 50 sub in mouse rat and rabbit is 340 mg kg 520 mg kg and 600 mg kg respectively Subcutaneous LD sub 50 sub in mouse and rat is 1600 mg kg and 1000 mg kg respectively Oral LD sub 50 sub in mouse and rat is 3000 mg kg and 1000 mg kg respectively Nephrotoxicity ototoxicity and retinal toxicity have been reported following long term administration for chronic iron overload",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Deferoxamine otherwise known as desferrioxamine or desferal is a chelating agent used to remove excess iron or aluminum from the body It acts by binding free iron or aluminum in the bloodstream and enhancing its elimination in the urine By removing excess iron or aluminum the agent reduces the damage done to various organs and tissues such as the liver",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00126",
                        "description": "The risk or severity of Cardiovascular Impairment can be increased when Ascorbic acid is combined with Deferoxamine"
                    },
                    {
                        "drugbank-id": "DB08830",
                        "description": "The risk or severity of Cardiovascular Impairment can be increased when Dehydroascorbic acid is combined with Deferoxamine"
                    },
                    {
                        "drugbank-id": "DB14482",
                        "description": "The risk or severity of Cardiovascular Impairment can be increased when Sodium ascorbate is combined with Deferoxamine"
                    },
                    {
                        "drugbank-id": "DB14483",
                        "description": "The risk or severity of Cardiovascular Impairment can be increased when Calcium ascorbate is combined with Deferoxamine"
                    },
                    {
                        "drugbank-id": "DB14485",
                        "description": "The risk or severity of Cardiovascular Impairment can be increased when Zinc ascorbate is combined with Deferoxamine"
                    },
                    {
                        "drugbank-id": "DB14486",
                        "description": "The risk or severity of Cardiovascular Impairment can be increased when Niacinamide ascorbate is combined with Deferoxamine"
                    },
                    {
                        "drugbank-id": "DB00433",
                        "description": "The risk or severity of adverse effects can be increased when Deferoxamine is combined with Prochlorperazine"
                    },
                    {
                        "drugbank-id": "DB09139",
                        "description": "Deferoxamine may decrease effectiveness of Technetium Tc 99m oxidronate as a diagnostic agent"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}